Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US - Analytic framework and review of the literature

被引:149
作者
Insinga, RP [1 ]
Dasbach, EJ [1 ]
Elbasha, EH [1 ]
机构
[1] Merck Res Labs, Dept Hlth Econ Stat, Blue Bell, PA 19422 USA
关键词
D O I
10.2165/00019053-200523110-00004
中图分类号
F [经济];
学科分类号
02 ;
摘要
The anogenital human papillomavirus (HPV) is estimated to be the most commonly occurring sexually transmitted infection in the US. Comprehensive estimates of the annual economic burden associated with the prevention and treatment of anogenital HPV-related disease in the US population are currently unavailable. The purpose of this paper is to (i) outline an analytic framework from which to estimate the annual economic burden of preventing and treating anogenital HPV-related disease in the US; (ii) review available US literature concerning the annual economic burden of HPV; and (iii) highlight gaps in current knowledge where further study is particularly warranted. Among eight US studies identified that describe the annual economic burden pertaining to one or more aspects of anogenital HPV-related disease, three met the review eligibility criteria (published between 1990 and 2004, examined multiple facets of annual anogenital HPV-related economic burden, and clearly articulated the data and methods used in the estimation process). All costs were adjusted to 2004 $US. Estimates of the annual direct medical costs associated with cervical cancer were comparable across studies (range $US300-400 million). In contrast, there was a wide range across studies for estimates of the annual direct medical costs associated with cervical intraepithelial neoplasia (range $US700 million-$US2.3 billion). Only one study reported direct medical costs for anogenital warts ($US200 million) and routine cervical cancer screening ($US2.3 billion). No studies examined direct medical costs attributable to HPV-related anal, penile, vaginal or vulvar cancers, or the work and productivity losses resulting from time spent receiving medical care, morbidity or mortality. Current economic burden estimates would suggest annual direct medical costs associated with the prevention and treatment of anogenital warts and cervical HPV-related disease of at least $US4 billion. This figure would likely rise to at least $US5 billion per year if direct medical costs associated with other disease entities caused by the sexual transmission of HPV were included, with further additions to the economic burden totalling in the billions of dollars if work and productivity losses were incorporated, a research priority for future studies.
引用
收藏
页码:1107 / 1122
页数:16
相关论文
共 107 条
  • [1] [Anonymous], CURR STAT DEV PROPH
  • [2] [Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P1
  • [3] Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle
    Armstrong, LR
    Preston, EJD
    Reichert, M
    Phillips, DL
    Nisenbaum, R
    Todd, NW
    Jacobs, IN
    Inglis, AF
    Manning, SC
    Reeves, WC
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 107 - +
  • [4] BECKER TM, 1987, OBSTET GYN CLIN N AM, V14, P389
  • [5] Genital warts and their treatment
    Beutner, KR
    Wiley, DJ
    Douglas, JM
    Tyring, SK
    Fife, K
    Trofatter, K
    Stone, KM
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 : S37 - S56
  • [6] Burden of migraine in Brazil: Estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care
    Bigal, ME
    Rapoport, AM
    Bordini, CA
    Tepper, SJ
    Sheftell, FD
    Speciali, JG
    [J]. HEADACHE, 2003, 43 (07): : 742 - 754
  • [7] The cost of juvenile-onset recurrent respiratory papillomatosis
    Bishai, D
    Kashima, H
    Shah, K
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2000, 126 (08) : 935 - 939
  • [8] Where do people go for treatment of sexually transmitted diseases?
    Brackbill, RM
    Sternberg, MR
    Fishbein, M
    [J]. FAMILY PLANNING PERSPECTIVES, 1999, 31 (01): : 10 - 15
  • [9] BROWN M, 1995, CANC PREVENTION CONT
  • [10] Brown Martin L, 2002, Med Care, V40, pIV, DOI 10.1097/00005650-200208001-00014